A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of Bosentan in Patients With Stage IV Metastatic Melanoma Treated With Dacarbazine
This is a randomized, double-blind (1:1 bosentan : placebo) trial to evaluate the effect of
bosentan in combination with DTIC on TTP or death in patients with metastatic melanoma stage
IV.
The patients will receive study medication (bosentan or placebo) and DTIC for 35 weeks to
105 weeks; the study will be completed when 66 events (tumor progression, death due to
underlying disease, other/additional anti-tumor therapy) have been observed.
Study drug will be administered orally, 500 mg twice a day. DTIC will be given once every
three weeks in a dosage of 1000 mg/m2 intravenously (i.v.) or in accordance with the
Institution's DTIC treatment protocol.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Time to tumor progression (TTP) or death (progression free survival) after initiation of treatment. Tumor progression is defined per RECIST criteria.
6 weekly
No
Andjela Kusic-Pajic, MD
Study Director
Actelion Pharmaceuticals Australia Pty. Ltd
Australia: Human Research Ethics Committee
AC-052-281
NCT01009177
September 2005
February 2008
Name | Location |
---|